Separate and combined effects of empagliflozin and semaglutide on vascular function: A 32-week randomized trial

What Was Tested

The paper reports a study of Semaglutide, published as a randomized controlled trial.

This study aimed to investigate the effect of empagliflozin, semaglutide, and their combination on vascular function.

Who Took Part

The abstract describes 120 patients taking part.

In total, 120 patients with type 2 diabetes were randomized into four groups (n = 30 in each) for 32 weeks: placebo, semaglutide, empagliflozin, and their combination.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The patients were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

Neither the patients nor the staff measuring them knew who was on Semaglutide, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Semaglutide could be set against what happens without it.

A time span of 32 weeks appears in the methods.

The study had two co-primary outcomes: change in arterial stiffness and kidney oxygenation.

This paper reports on arterial stiffness assessed as carotid-femoral pulse wave velocity.

Secondary outcomes included 24-h blood pressure (BP), 24-h central BP, urinary albumin to creatinine ratio and glycaemic control assessed by both continuous glucose monitoring and glycated haemoglobin.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 2, Hypoglycemic Agents, Creatinine, Blood Glucose Self-Monitoring, Pulse Wave Analysis, Blood Glucose and Benzhydryl Compounds.

The authors tagged it with the keywords continuous glucose monitoring, drug mechanism, glucagon‐like peptide‐1 analogue, macrovascular disease, sodium–glucose cotransporter 2 inhibitor and type 2 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Semaglutide in 120 patients over 32 weeks.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Semaglutide compound page, all human trials.